• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Ophthalmic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2018 Product Image

Ophthalmic Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2018

  • Published: January 2014
  • Region: Global
  • 72 Pages
  • Transparency Market Research

FEATURED COMPANIES

  • Allergan
  • Merck
  • Novartis
  • Pfizer
  • Roche
  • Santen Pharmaceutical
  • MORE

'Ophthalmic Drugs Market (Dry eye, Anti-glaucoma, Anti-allergy/inflammatory/infective, Retinal Drugs) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2018'

The global ophthalmic drugs market is rapidly growing due to increasing prevalence of eye disorders such as glaucoma, dry eye diseases and retinal diseases. Changing lifestyle, improved medical infrastructure, technological changes, increase in healthcare spending and aging population is also supporting the growth of the ophthalmic drugs market.

Glaucoma is the largest drugs segment in global ophthalmic drugs market. Some of the major drugs for glaucoma treatment are Lumigan, Combigan, Xalatan, Ganfort and Saflutan. Diquas, Hyalein and Restasis are the major drugs for dry eye diseases. The retinal drugs market includes Ozurdex, Macugen, Visudyne and Lucentis. Patanol/Pataday, Tobradex, Vigamox and Bepreve are major ocular anti-inflammatory drugs. The ophthalmic drugs market covers prescription based drugs, OTC drugs and pipeline drugs. This report forecasts future potential of all these drug markets and analyses drivers and opportunities, restraints and challenges, market trends, Porter’s READ MORE >

Chapter 1 Preface
1.1 Report Description
1.2 Research Methodology

Chapter 2 Executive Summary

Chapter 3 Ophthalmic Drugs – Industry Analysis
3.1 Introduction
3.2 Market Drivers and Opportunities
3.2.1 Increasing prevalence of eye disorders
3.2.2 Global aging population
3.2.3 Rising government initiatives towards healthcare infrastructure in developing countries
3.2.4 Technological changes in drug delivery techniques
3.2.5 Increasing prevalence of lifestyle associated diseases
3.3 Restraints and Challenges
3.3.1 Lack of awareness among people regarding eye disorders
3.3.2 Drying pipeline of ophthalmic drugs
3.3.3 Patent expiration of blockbuster ophthalmic drugs
3.3.4 Absence of health insurance in developing countries

Chapter 4 Ophthalmic Drugs Market Trends
4.1 Increased focus on combination therapy
4.2 Increasing mergers and acquisitions contribute to the growth of ophthalmic drugs market

Chapter 5 Porter’s Five Force Analysis
5.1 Bargaining power of buyers
5.2 Bargaining power of suppliers
5.3 Threat of new entrants
5.4 Threat from substitutes
5.5 Degree of competition

Chapter 6 Global Market Size and Forecast

Chapter 7 Ophthalmic Drugs Market – Treatment Drugs
7.1 Dry eye drugs
7.1.1 Existing
7.1.2 Pipeline
7.2 Retinal drugs
7.2.1 Existing
7.2.2 Pipeline
7.3 Ophthalmic anti-allergy/ inflammatory/ infective drugs
7.3.1 Existing
7.3.2 Pipeline
7.4 Anti-glaucoma drugs
7.4.1 Existing
7.4.2 Pipeline

Chapter 8 Ophthalmic Drugs Market: Regional Analysis
8.1 Scenario in North America
8.1.1 Scenario in the US
8.2 Scenario in Europe
8.2.1 Scenario in France
8.2.2 Scenario in Germany
8.2.3 Scenario in the UK
8.3 Scenario in Asia Pacific
8.3.1 Scenario in India
8.3.2 Scenario in China
8.3.3 Scenario in Japan

Chapter 9 Prescription vs. Over the Counter Drugs

Chapter 10 Competitive Landscape

Chapter 11 Company Profiles
11.1 Santen Pharmaceutical
11.1.1 Overview
11.1.2 Products and segments
11.1.3 Financial Performance
11.2 Pfizer
11.2.1 Overview
11.2.2 Products & Segments
11.2.3 Financial Performance
11.3 Novartis
11.3.1 Overview
11.3.2 Products & Segments
11.3.3 Financial Performance
11.4 Merck
11.4.1 Overview
11.4.2 Products & Segments
11.4.3 Financial Performance
11.5 Roche
11.5.1 Overview
11.5.2 Products & Segments
11.5.3 Financial Performance
11.6 Allergan
11.6.1 Overview
11.6.2 Products & Segments
11.6.3 Financial Performance

List of Figures

FIG. 1 Profiles of aging population in major countries (%, 2000-2050)
FIG. 2 Global ophthalmic drugs market: Porter’s five force analysis
FIG. 3 Key players market share in the global ophthalmic drugs market in 2012
FIG. 4 Ophthalmic drugs market strategic developments (2011-2013)

List of Tables

TABLE 1 Drivers for ophthalmic drugs market: Impact analysis
TABLE 2 Global data on visual impairment, by region (million, 2002 and 2010)
TABLE 3 Restraints for ophthalmic drugs market: Impact analysis
TABLE 4 Out of pocket expenditure of developing and developed countries
TABLE 5 Major combination therapy drugs worldwide
TABLE 6 Major merger and acquisitions in the ophthalmic drug market
TABLE 7 Global Ophthalmic drugs market size, by geography 2008-2012 (USD million)
TABLE 8 Global Ophthalmic drugs market size, by geography 2013-2018(USD millions)
TABLE 9 Global Ophthalmic drugs market size, by disease 2008-2012 (USD million)
TABLE 10 Global Ophthalmic drugs market size, by disease 2013-2018 (USD million)
TABLE 11 Dry eye drugs market 2010-2012 (USD million)
TABLE 12 Dry eye drugs market 2013-2018 (USD million)
TABLE 13 Major dry eye drugs pipeline
TABLE 14 Retinal drugs market 2010-2012 (USD million)
TABLE 15 Retinal drugs market 2013-2018 (USD million)
TABLE 16 Major retinal disease drugs pipeline
TABLE 17 Anti-allergy/inflammatory drugs market 2010-2012 (USD million)
TABLE 18 Anti-allergy/inflammatory drugs market 2013-2018 (USD million)
TABLE 19 Major anti-inflammatory/allergy/anti-infective drugs pipeline
TABLE 20 Prevalence of glaucoma, by geographic regions (million, 2010-2020)
TABLE 21 Major anti-glaucoma drugs market 2010-2012 (USD million)
TABLE 22 Major anti-glaucoma drugs market 2013-2018 (USD million)
TABLE 23 Anti-glaucoma drugs pipeline
TABLE 24 North America Ophthalmic drugs market size, by geography 2008-2012 (USD million)
TABLE 25 North America Ophthalmic drugs market size, by geography 2013-2018 (USD million)
TABLE 26 North America Ophthalmic drugs market size, by disease 2008-2012 (USD million)
TABLE 27 North America ophthalmic drugs market, by disease 2013-2018 (USD million)
TABLE 28 Ophthalmic drugs market, by disease in US 2008-2012(USD million)
TABLE 29 Ophthalmic drugs market by disease in US 2013-2018 (USD million)
TABLE 30 European Ophthalmic drugs market size, by geography 2008-2012 (USD million)
TABLE 31 European Ophthalmic drugs market size, by geography 2013-2018 (USD million)
TABLE 32 European ophthalmic drugs market by disease 2008-2012 (USD million)
TABLE 33 European ophthalmic drugs market by disease 2013-2018 (USD million)
TABLE 34 French ophthalmic drugs market by disease 2008-2012 (USD million)
TABLE 35 French ophthalmic drugs market, by disease 2013-2018 (USD million)
TABLE 36 German Ophthalmic drugs market, by disease 2008-2012 (USD million)
TABLE 37 German ophthalmic drugs market, by disease 2013-2018 (USD million)
TABLE 38 The UK ophthalmic drugs market, by disease 2008-2012 (USD million)
TABLE 39 The UK ophthalmic drugs market, by disease 2013-2018 (USD million)
TABLE 40 Asian Ophthalmic drugs market size, by country 2008-2012 (USD million)
TABLE 41 Asian Ophthalmic drugs market size, by geography 2013-2018 (USD million)
TABLE 42 Asian ophthalmic drugs market, by disease 2008-2012 (USD million)
TABLE 43 Asian ophthalmic drugs market, by disease 2013-2018 (USD million)
TABLE 44 Indian ophthalmic drugs market, by disease 2008-2012 (USD million)
TABLE 45 Indian ophthalmic drugs market, by disease 2013-2018 (USD million)
TABLE 46 Chinese ophthalmic drugs market, by disease 2008-2012 (USD million)
TABLE 47 Chinese ophthalmic drugs market, by disease 2013-2018 (USD million)
TABLE 48 Japanese ophthalmic drugs market, by disease 2008-2012 (USD million)
TABLE 49 Japanese ophthalmic drugs market, by disease 2013-2018 (USD million)
TABLE 50 Ophthalmic drugs market, by prescription vs. over the counter drugs 2008-2012 (USD million)
TABLE 51 Ophthalmic drugs market, by prescription vs. over the counter drugs 2013-2018 (USD million)
TABLE 52 Major product launches in ophthalmic drugs market (2011-2013)
TABLE 53 R&D initiatives in ophthalmic drugs market (2012-2013)
TABLE 54 Mergers and acquisitions in ophthalmic drugs market (2011-2013)

Globally, the ophthalmic drugs market is witnessing significant growth due to increasing prevalence of eye disorders such as diabetic retinopathy and macular degeneration. As a result, this market is expected to grow at a CAGR of about 5.2% during 2013 – 2018.

Some of the key driving factors for the ophthalmic drugs market are rising prevalence of global aging population, increasing government initiatives towards healthcare infrastructure in developing countries (such as India and China), technological changes in drug delivery technique, and increasing prevalence of lifestyle associated diseases. However, the market faces some restraints such as lack of awareness among people regarding eye disorders, drying pipeline of ophthalmic drugs, patent expiration of blockbuster ophthalmic drugs and absence of health insurance in developing countries.

North America, including the US has the largest ophthalmic drugs market, while Asia is the fastest growing ophthalmic drugs market. Some of the fastest growing markets for ophthalmic drugs are China, India, other countries in South East Asia and the Eastern Mediterranean. As per WHO estimates in 2010, in the next nine years, the number of blind people aged 50 years and above will grow in these regions, thereby increasing the demand for ophthalmic drugs. On the other hand, in developed regions such as North America and Western Europe, rising efforts towards prevention of blindness among the aging population has emerged as a key driver for the market.

Glaucoma has the largest market share in the ophthalmic drugs market and it is expected to grow at a CAGR of about 4.2% during 2013 – 2018. Various ophthalmic drug companies are increasing their focus on combination therapy, which involves use of more than one medication for specific retinal disorders. Most of these combination therapies are used as first line treatment in patients with high level of intraocular pressure. Combination therapy has various advantages over traditional medication such as reduced frequency of eye drop application, improved patient compliance and efficacy.

Novartis (Alcon) is the leading player in the global ophthalmic drugs market while other major players include Allergan, Santen, Pfizer, Merck and Roche.

- Allergan
- Merck
- Novartis
- Pfizer
- Roche
- Santen Pharmaceutical

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos